• Wondering if Corcept Therapeutics at around US$41.91 is a bargain or fully priced? This article breaks down what the current share price might be implying about value.
• The stock has had mixed returns, with a 30 day gain of 30.4% and a 1 year return of 38.9% decline, while still showing 89.0% and 84.1% returns over 3 and 5 years.
• That kind of swing often reflects changing views on the company, shifts in sentiment toward its pharmaceutical pipeline, or reactions to regulatory and competitive developments. Recent news coverage has focused on how Corcept fits into the broader biotech space and the potential implications of its product portfolio and research focus for future pricing and risk.
• Corcept currently has a valuation score of 2 out of 6. The sections ahead will walk through traditional valuation checks before ending with a broader way to think about what that score really means for you.

Corcept Therapeutics scores just 2/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

Approach 1: Corcept Therapeutics Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model projects a company’s future cash flows and then discounts them back to today to estimate what the business might be worth right now.

For Corcept Therapeutics, the latest twelve month Free Cash Flow is about $141 million. Analysts have supplied cash flow estimates out to 2030, and Simply Wall St extends these with its own assumptions to create a 2 Stage Free Cash Flow to Equity model. Within that model, projected Free Cash Flow in 2035 is $1,992.3 million, with interim years such as 2030 at $810.4 million, all expressed in $.

After discounting these projected cash flows, the model arrives at an estimated intrinsic value of about $332.45 per share. Compared with the recent share price around $41.91, this output indicates the stock is 87.4% undervalued according to this particular DCF setup.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Corcept Therapeutics is undervalued by 87.4%. Track this in your watchlist or portfolio, or discover 58 more high quality undervalued stocks.

Approach 2: Corcept Therapeutics Price vs Earnings

For profitable companies, the P/E ratio is a straightforward way to link what you pay for each share to the earnings that support that share. It helps you see how much the market is willing to pay for every dollar of profit. Higher growth expectations and lower perceived risk usually justify a higher “normal” P/E, while slower expected growth or higher risk typically lines up with a lower one.

Corcept Therapeutics is currently trading on a P/E of 45.41x. That sits above the Pharmaceuticals industry average of 16.97x and above the peer average of 32.89x, which indicates the stock is priced at a higher earnings multiple than many sector peers. Simply Wall St also calculates a Fair Ratio of 33.12x, which is the P/E level suggested by factors such as Corcept’s earnings growth profile, profit margins, industry, market cap and risk characteristics.

This Fair Ratio is more tailored than a simple peer or industry comparison because it adjusts for company specific traits rather than assuming all firms deserve similar multiples. Comparing Corcept’s current P/E of 45.41x with the Fair Ratio of 33.12x indicates the shares are trading above that model-based estimate.

Result: OVERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 18 top founder-led companies.

Upgrade Your Decision Making: Choose your Corcept Therapeutics Narrative

Earlier it was mentioned that there is an even better way to understand valuation, so Narratives are introduced here as a simple way for you to attach a clear story about Corcept Therapeutics to numbers such as fair value, future revenue, earnings and margins, then link that story to a financial forecast and finally to a fair value that can be compared with the current share price.

On Simply Wall St's Community page, Narratives are an easy tool used by millions of investors. They let you see and create different stories about Corcept, and each one is tied to its own forecast. When new information such as news, earnings or guidance arrives, those Narratives and their fair values update automatically and help you decide whether the latest price looks high, low or roughly in line with your view.

For example, one Corcept Narrative applies a fair value of US$63.53 and another more optimistic one applies US$121.00. This shows how two investors looking at the same business and information can reasonably land on very different views, and your job is to decide which story, and which implied fair value, feels closest to your own expectations.

Do you think there's more to the story for Corcept Therapeutics? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.